EcoDrugPlus

Ttk Protein Kinase

Ensembl ID : ENSBTAG00000005456
Gene Symbol: TTK
5 Cross references
217 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSBTAG00000016073
Gene Symbol: UGCG
4 Enzyme and pathways 5 Cross references
224 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSBTAG00000005278
Gene Symbol: WEE1
16 Enzyme and pathways 5 Cross references
239 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSBTAG00000001523
Gene Symbol: YES1
23 Enzyme and pathways 5 Cross references
272 Possible Orthologues:

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSBTAG00000001139
Gene Symbol: ACHE
4 Cross references
246 Possible Orthologues:

Activin A Receptor Like Type 1

Ensembl ID : ENSBTAG00000013843
Gene Symbol: ACVRL1
3 Enzyme and pathways 5 Cross references
370 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSBTAG00000018105
Gene Symbol: ACVR2B
4 Enzyme and pathways 5 Cross references
271 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSBTAG00000011461
Gene Symbol: ADORA1
8 Enzyme and pathways 5 Cross references
284 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSBTAG00000016944
Gene Symbol: ADORA2A
10 Enzyme and pathways 5 Cross references
276 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSBTAG00000007581
Gene Symbol: ADORA2B
10 Enzyme and pathways 5 Cross references
212 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSBTAG00000005280
Gene Symbol: ADA
6 Enzyme and pathways 5 Cross references
231 Possible Orthologues:

Adrenoceptor Alpha 1a

Ensembl ID : ENSBTAG00000031632
Gene Symbol: ADRA1A
9 Enzyme and pathways 5 Cross references
213 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).